Brief: Plasma pTau Identified as Key Early Endpoint in Alzheimer's Research
01/12/2025 12:36
Dec 1 (Reuters) - ProMIS Neurosciences Inc PMN.O: PROMIS NEUROSCIENCES ANNOUNCES NEW PEER-REVIEWED PUBLICATION SHOWING PLASMA PTAU AS A PREDICTIVE EARLY ENDPOINT IN ALZHEIMER’S TRIALS, SUPPORTING ITS ONGOING PHASE 1B PRECISE-AD TRIAL WITH PMN310 Source text: ID:nGNX8FkrMG Further company coverage: PMN.O ((Reuters.Briefs@thomsonreuters.com;))